Reuters logo
BRIEF-Ligand's partner Retrophin reports additional positive data from phase 2 duet study of sparsentan in focal segmental glomerulosclerosis at asn kidney week 2016
2016年11月21日 / 下午12点47分 / 10 个月前

BRIEF-Ligand's partner Retrophin reports additional positive data from phase 2 duet study of sparsentan in focal segmental glomerulosclerosis at asn kidney week 2016

Nov 21 (Reuters) - Ligand Pharmaceuticals Inc :

* Data shows statistically significant difference in modified partial remission; complete remission also observed

* Further analysis supports sparsentan generally safe and well-tolerated

* Press release - Ligand’s partner Retrophin reports additional positive data from phase 2 duet study of sparsentan in focal segmental glomerulosclerosis at asn kidney week 2016 Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below